Curis Inc
$ 1.01
-2.88%
30 Dec - close price
- Market Cap 13,058,100 USD
- Current Price $ 1.01
- High / Low $ 1.07 / 0.96
- Stock P/E N/A
- Book Value -1.15
- EPS -3.30
- Next Earning Report -
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA -0.61 %
- ROE -29.51 %
- 52 Week High 4.50
- 52 Week Low 0.96
About
Curis, Inc. (Ticker: CRIS), based in Lexington, Massachusetts, is a biotechnology company dedicated to developing innovative targeted therapies for oncology, addressing critical unmet medical needs. Utilizing proprietary platforms, Curis has established a robust pipeline of promising drug candidates aimed at improving treatment outcomes for various types of cancer. With a strong commitment to research and development, Curis is well-positioned to make significant contributions to the future of cancer care, striving to tackle the intricacies of cancer treatment and enhance the quality of life for patients.
Analyst Target Price
$14.00
Quarterly Earnings
| Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | Mar 2023 | Dec 2022 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2025-11-06 | 2025-08-05 | 2025-05-05 | 2025-03-31 | 2024-11-01 | 2024-08-01 | 2024-05-07 | 2024-02-08 | 2023-11-02 | 2023-08-03 | 2023-05-04 | 2023-03-13 |
| Reported EPS | -0.49 | -0.68 | -1.2538 | -1.25 | -1.7 | -2.03 | -2.05 | -2.03 | -2.13 | -0.12 | -0.12 | -0.12 |
| Estimated EPS | -1.31 | -1.24 | -1.2633 | -0.99 | -1.84 | -1.67 | -2.12 | -2.11 | -2.33 | -0.12 | -0.1 | -0.13 |
| Surprise | 0.82 | 0.56 | 0.0095 | -0.26 | 0.14 | -0.36 | 0.07 | 0.08 | 0.2 | 0 | -0.02 | 0.01 |
| Surprise Percentage | 62.5954% | 45.1613% | 0.752% | -26.2626% | 7.6087% | -21.5569% | 3.3019% | 3.7915% | 8.5837% | 0% | -20% | 7.6923% |
Next Quarterly Earnings
| Reported Date |
| Fiscal Date Ending |
| Estimated EPS |
| Currency |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: CRIS
2025-12-09 08:00:00
Curis, Inc. presented updated clinical data from its frontline Acute Myeloid Leukemia (AML) triplet study at the 67th ASH Annual Meeting. The data showed that 5 of 8 patients (62.5%) achieved undetectable MRD, an improvement from initial reports, with an unchanged safety profile. The study evaluates the addition of emavusertib to venetoclax and azacitidine in MRD-positive AML patients to achieve undetectable MRD.
2025-11-24 03:44:23
Curis, Inc. (CRIS) shares have dropped 28% recently, bringing its price-to-sales (P/S) ratio to 1.3x, which appears low compared to the biotech industry average. However, despite modest revenue growth of 14% last year and a projected 51% annual growth over the next three years, this is still significantly lower than the industry's predicted 124% growth, making the low P/S ratio understandable. Investors are likely cautious due to the company's weaker growth outlook compared to its peers.
2025-11-23 03:09:15
Curis, Inc. (NASDAQ:CRIS) has seen a significant 28% reduction in its share price over the past month, leading to a year-to-date decline of 69%. While its current price-to-sales (P/S) ratio of 1.3x appears low compared to the biotech industry average, it reflects investor concerns about the company's forecasted revenue growth, which is expected to be significantly lower than the industry average. Despite some historical revenue growth, analysts predict Curis's future growth will not be strong enough to warrant a higher P/S ratio.
2025-11-18 05:09:58
Curis (NASDAQ: CRIS) announced it will present clinical and preclinical data on its oral IRAK4 inhibitor, emavusertib (CA-4948), at the 30th Annual Society for Neuro-Oncology (SNO) Meeting from November 19-23, 2025. The presentations will cover emavusertib's efficacy in Primary CNS Lymphoma (PCNSL) and Secondary CNS Lymphoma (SCNSL), as well as targeting Myddosome signaling in melanoma brain metastases. The news led to a significant positive market reaction, with CRIS stock gaining 17.70% on the day of publication.
2025-11-14 09:26:00
Curis, Inc. (NASDAQ: CRIS) announced it will present emavusertib and BTKi clinical data in Primary CNS Lymphoma (PCNSL) and Secondary CNS Lymphoma (SCNSL) in three presentations, along with preclinical data on emavusertib in an oral presentation, at the 30th Annual Meeting of the Society for Neuro-Oncology (SNO) from November 19-23, 2025. The presentations will cover analysis of genetic mutation profiles, CNS pharmacokinetics, and preliminary safety and efficacy data for emavusertib in combination with ibrutinib in relapsed/refractory PCNSL and SCNSL patients, as well as targeting Myddosome signaling to improve immunotherapy in melanoma brain metastases. Curis is a biotechnology company developing emavusertib, an orally available, small molecule IRAK4 inhibitor for various cancers.
2025-10-03 16:00:00
Curis, Inc. announced the grant of inducement stock options to two new employees on October 1, 2025, to purchase a total of 84,750 shares of common stock. These grants were approved by the Compensation Committee of the Board of Directors and comply with NASDAQ Listing Rule 5635(c)(4). The stock options have a 10-year term and vest over four years, serving as material inducement for the employees' acceptance of employment.
